168 - Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease

Thursday, October 17, 2024

2:33 PM – 2:45 PM US PT

Location: 403 A

Presenting Author(s)

HQ

Hui Qian, PhD

Moderna, Inc.
Cambridge, Massachusetts, United States
HC

HuiLing Chen, PhD

Moderna, Inc.
Cambridge, Massachusetts, United States
JW

Joseph Whitten, MD

Moderna, Inc.
Cambridge, Massachusetts, United States
SS

Sonia K. Stoszek, PhD

Moderna, Inc.
Cambridge, Massachusetts, United States
Matthew D. Snape, MBBS, MD, FRCPCH, FPM, FMedSci

Vice President, Clinical Development, Pediatric and Maternal Vaccines
Moderna Biotech UK, Inc
Didcot, England, United Kingdom

Disclosure(s):

Sabine Schnyder Ghamloush, MD: Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Hui Qian, PhD: Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

HuiLing Chen, PhD: Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Joseph Whitten, MD: Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Sonia K. Stoszek, PhD: Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Matthew D. Snape, MBBS, MD, FRCPCH, FPM, FMedSci: Moderna, Inc.: Emplolyee, Stocks/Bonds (Public Company)